No Data
No Data
Correction to Select Medical Outlook Headline on July 12
Select Medical expects Concentra's net operating revenue for its second quarter of 2024 to be about $477.92 million. The headline "Select Medical Sees 2Q Rev $477.92M >SEM," published at 4:30 p.m.
A Glimpse Into The Expert Outlook On Select Medical Hldgs Through 4 Analysts
In the last three months, 4 analysts have published ratings on Select Medical Hldgs (NYSE:SEM), offering a diverse range of perspectives from bullish to bearish.The following table summarizes their
Select Medical Is Maintained at Buy by Benchmark
Select Medical Is Maintained at Buy by
Benchmark Maintains Buy on Select Medical Hldgs, Raises Price Target to $48
Benchmark analyst Bill Sutherland maintains Select Medical Hldgs (NYSE:SEM) with a Buy and raises the price target from $42 to $48.
Select Medical Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/16/2024 25.29% Benchmark $42 → $48 Maintains Buy 05/06/2024 4.41% RBC Capital $36 → $40 Maintains
Benchmark Co. Maintains Select Medical Holdings(SEM.US) With Buy Rating, Raises Target Price to $48
Benchmark Co. analyst Bill Sutherland maintains $Select Medical Holdings(SEM.US)$ with a buy rating, and adjusts the target price from $42 to $48.According to TipRanks data, the analyst has a